Revenue Breakdown
Composition ()
No data
Revenue Streams
Cryoport Inc (CYRX) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Life Science products, accounting for 45.2% of total sales, equivalent to $19.98M. Other significant revenue streams include BioLogistics solutions and BioStorage/Bioservices. Understanding this composition is critical for investors evaluating how CYRX navigates market cycles within the Courier, Postal, Air Freight & Land-based Logistics industry.
Profitability & Margins
Evaluating the bottom line, Cryoport Inc maintains a gross margin of 48.21%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -22.45%, while the net margin is -15.14%. These profitability ratios, combined with a Return on Equity (ROE) of -14.12%, provide a clear picture of how effectively CYRX converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, CYRX competes directly with industry leaders such as RLGT and FLX. With a market capitalization of $411.07M, it holds a leading position in the sector. When comparing efficiency, CYRX's gross margin of 48.21% stands against RLGT's 25.80% and FLX's 11.12%. Such benchmarking helps identify whether Cryoport Inc is trading at a premium or discount relative to its financial performance.
